Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients
NCT ID: NCT02499250
Last Updated: 2015-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2015-01-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improvement of Cardiac Function in Patients With Ischemic Cardiomyopathy by Extracorporeal Shock Wave Therapy: a Multicenter Clinical Study
NCT03398096
Routinely Deferred Versus Early Intervention in Elderly Patients With Non-ST-elevation Myocardial Infarction
NCT02900001
Evaluation of Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction
NCT02641184
Myocardial Work for Prediction of Left Ventricular Remodeling in Patients With STEMI
NCT05107102
Diagnostic and Prognostic Value of Angiography-derived IMR
NCT04825028
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RIPC arm
The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive daily remote ischemic conditioning plus optimal medical treatment over 30 days.
remote ischemic conditioning (TDFT-12-A2)
The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the "TDFT-12-A2" device produced by "Shenzhen TDF Tai Smart technology Co., Ltd."
Optimal medical treatment
The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Control arm
The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive optimal medical treatment over 30 days.
Optimal medical treatment
The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
remote ischemic conditioning (TDFT-12-A2)
The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the "TDFT-12-A2" device produced by "Shenzhen TDF Tai Smart technology Co., Ltd."
Optimal medical treatment
The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No chance of further revascularization or refusal to do revascularization;
* The frequency and Canadian Cardiovascular Society (CCS) scale stays stable over the past 3 months before inclusion.
Exclusion Criteria
* Infection or fever in the past month;
* Blood pressure over 180/110 millimeters of mercury (mmHg) or below 80/50mmHg;
* Refusal to comply with the study protocol;
* Currently under sulfonylureas or prostaglandins therapy;
* Other conditions that the researchers judge as inappropriate to participate.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Navy General Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Zhao MD,PhD
attending physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tianchang Li, MD, PhD
Role: STUDY_CHAIR
Heart center, Navy General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Heart Center, Navy General Hospital of PLA
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HZKY-PJ-2014-1-A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.